Methazolamide
A carbonic anhydrase inhibitor used to lower elevated intraocular (eye) pressure in people with glaucoma who cannot tolerate or do not respond adequately to other treatments. It helps prevent vision loss by reducing fluid buildup in the eye.
Peso Molecular
236,3000 g/mol
LogP
0,10
TPSA
139,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C
InChI
InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+
Molecular Formula
C5H8N4O3S2
HBD / HBA
1 / 6
Ligações Rotacionáveis
1
Átomos Pesados
14
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A carbonic anhydrase inhibitor used to lower elevated intraocular (eye) pressure in people with glaucoma who cannot tolerate or do not respond adequately to other treatments. It helps prevent vision loss by reducing fluid buildup in the eye.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Methazolamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL19. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4100. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="methazolamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/methazolamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/methazolamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/methazolamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="methazolamide"></drugfyi-drug>